% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • twelvetooth twelvetooth Jan 3, 2013 9:10 AM Flag

    Will Nexavar thyroid treatment compete with EXEL ?

    Today, Bayer said its cancer treatment Nexavar reached a goal of improving the survival of patients with a certain type of thyroid cancer in a late-stage clinical trial..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Maybe, but in an indirect way.

      There are currently no TKI's approved to treat differentiated thyroid cancer, yet TKI efficacy has been demonstrated in various phase 2 trials. To cover this gap in the approval process, the NCCN thyroid committee recommends the off label use of 3 TKI's already approved for other indications, namely Nexavar, Sutent and Votrient. By virtue of having done so, DTC patients can get reimbursement for those drugs prescribed off label.

      Nexavar is the first TKI to complete a phase 3 trial in this indication, as such, its evidence of efficacy essentially trumps the various phase 2 trials that formed the basis for the NCCN compendia listing. EXEL will likely submit Comet for consideration for DTC compendia listing at the next NCCN thyroid committee meeting. Prior to the Nexavar phase 3 result, I would have bet on Comet being added to the compendia for DTC treatment, now I would say its more complicated. The Nexavar data has not been released so the committee is left a bit in the dark. They can add Comet to the list, they can leave the list unchanged, or thay can remove all the TKI's except Nexavar. Even if Comet is added to the compendia, oncologists will likely prescribe the Nexavar far more often than the competing off label TKI's, including Comet.

    • Completely different type of thyroid cancer and irrelevant to EXEL. Cabo treats medullary ca of the thyroid. Nexavar is for papillary and well differentiated forms of thyroid cancer

14.89+0.51(+3.43%)Sep 23 4:00 PMEDT